Zymeworks to meet investors in Miami
Zymeworks Inc., a biotechnology company based in Vancouver, will take part in two investor meetings in Miami, Florida. The company will attend the Evercore 8th Annual Healthcare Conference on December 2 and the Citi 2025 Global Healthcare Conference on December 3. At both events, Zymeworks’ leaders will join fireside chats and hold one-on-one meetings with investors. The company’s session at the Evercore conference will be held at 10:00 a.m. ET, while the Citi conference session is planned for 3:15 p.m. ET the next day. These meetings will allow investors to ask direct questions about the company’s recent progress, its expected timelines, and its financial priorities.
Company highlights progress
Zymeworks is developing several new biotherapeutics for cancer, inflammatory disorders, and autoimmune diseases. Its main program is Ziihera, a drug that targets HER2 and is built using the company’s Azymetric technology. This technology allows the drug to bind to two targets at the same time. Ziihera is licensed to BeOne Medicines Ltd. and Jazz Pharmaceuticals Ireland Limited in separate territories. In addition to Ziihera, Zymeworks is advancing other candidates such as pasritamig and several early-stage programs. The company aims to build a portfolio of licensed products that provide steady long-term revenue while also supporting new research projects.
Partnerships remain key to company strategy
Zymeworks uses an asset and royalty model to support its work. This model helps the company earn steady income while it continues to develop new drugs. The company also works with major biopharmaceutical partners around the world. These partners give Zymeworks more resources and technical support. They also help the company move its research programs forward faster. Zymeworks says its goal is to create treatments for patients with serious diseases. The investor meetings in Miami will allow the company to explain how its partnerships and drug programs support this plan.
